Increased risk of developing atrophic gastritis in patients infected with CagA+ Helicobacter pylori. 2001

N Sande, and M Nikulin, and I Nilsson, and T Wadström, and F Laxén, and M Härkönen, and O Suovaniemi, and P Sipponen
Dept. of Clinical Chemistry, Helsinki University Central Hospital, Finland.

BACKGROUND To clarify the possible role of CagA positive (CagA+) Helicobacter pylori strains in the development of atrophic gastritis, the prevalence of antibodies to H. pylori and CagA (120 kD protein) was studied among subjects with atrophic and non-atrophic gastritis. METHODS The study population was randomly selected among 12,252 Finnish men who were screened for atrophic corpus gastritis with serum pepsinogen I-assay (S-PGI). S-PGI level was used as a selection criterion. Group A consisted of 295 subjects with S-PGI <25 microg/l (low), group B of 320 subjects with S-PGI 25-100 microg/l (normal) and group C of 338 subjects with S-PGI >100 microg/l (high). Antibodies to H. pylori were measured with EIA and immunoblot analysis and antibodies to CagA with immunoblot analysis. Endoscopical and histological examinations were performed for 203 patients from group A. RESULTS The prevalence of antibodies to H. pylori was significantly lower in group B than in groups A or C (P < 0.0001, chi-squared test). There was a significant association between the prevalence of antibodies to CagA and the lowered level of S-PGI (P < 0.0001, Jonckheere-Terpstra trend test). There was also a linear decrease in the prevalence of antibodies to CagA as the atrophic corpus gastritis became more severe (P < 0.0001, linear-by-linear trend test). CONCLUSIONS The presence of antibodies to CagA seems to be associated with development of atrophic corpus gastritis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D005757 Gastritis, Atrophic GASTRITIS with atrophy of the GASTRIC MUCOSA, the GASTRIC PARIETAL CELLS, and the mucosal glands leading to ACHLORHYDRIA. Atrophic gastritis usually progresses from chronic gastritis. Atrophic Gastritides,Atrophic Gastritis,Gastritides, Atrophic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D000942 Antigens, Bacterial Substances elaborated by bacteria that have antigenic activity. Bacterial Antigen,Bacterial Antigens,Antigen, Bacterial
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity

Related Publications

N Sande, and M Nikulin, and I Nilsson, and T Wadström, and F Laxén, and M Härkönen, and O Suovaniemi, and P Sipponen
June 2022, Helicobacter,
N Sande, and M Nikulin, and I Nilsson, and T Wadström, and F Laxén, and M Härkönen, and O Suovaniemi, and P Sipponen
December 1995, Journal of the National Cancer Institute,
N Sande, and M Nikulin, and I Nilsson, and T Wadström, and F Laxén, and M Härkönen, and O Suovaniemi, and P Sipponen
June 1996, Journal of the National Cancer Institute,
N Sande, and M Nikulin, and I Nilsson, and T Wadström, and F Laxén, and M Härkönen, and O Suovaniemi, and P Sipponen
April 1996, Journal of the National Cancer Institute,
N Sande, and M Nikulin, and I Nilsson, and T Wadström, and F Laxén, and M Härkönen, and O Suovaniemi, and P Sipponen
July 1996, Journal of the National Cancer Institute,
N Sande, and M Nikulin, and I Nilsson, and T Wadström, and F Laxén, and M Härkönen, and O Suovaniemi, and P Sipponen
November 2008, World journal of gastroenterology,
N Sande, and M Nikulin, and I Nilsson, and T Wadström, and F Laxén, and M Härkönen, and O Suovaniemi, and P Sipponen
January 1997, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
N Sande, and M Nikulin, and I Nilsson, and T Wadström, and F Laxén, and M Härkönen, and O Suovaniemi, and P Sipponen
January 2002, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru,
N Sande, and M Nikulin, and I Nilsson, and T Wadström, and F Laxén, and M Härkönen, and O Suovaniemi, and P Sipponen
November 2005, Nihon rinsho. Japanese journal of clinical medicine,
N Sande, and M Nikulin, and I Nilsson, and T Wadström, and F Laxén, and M Härkönen, and O Suovaniemi, and P Sipponen
May 1992, The Tokai journal of experimental and clinical medicine,
Copied contents to your clipboard!